Company
ASX:NOX
Noxopharm Limited is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines. The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).
93 stories · page 3 of 5
Hudson Institute of Medical Research has been awarded a Victorian Government grant to fund research into novel therapeutics that block inflammation associated with long COVID.
This grant will fund the laboratory work to establish the therapeutic efficacy of these novel oligonucleotide TLR7 inhibitors in several animal models as well as in primary human cells derived from SLE patients.
It is my hope that our work will contribute to the development of new treatments for nasopharyngeal carcinoma," says lead researcher Professor Dora Kwong, commenting on the acceptance of the work as part of ASCO 2022, the leading clinical o
“The seven-year period of market exclusivity is commercially extremely valuable, as it means that the FDA will not approve a subsequent drug for the same use within this timeframe,” says CEO.
The study investigates NOX's flagship treatment, Veyonda, in combination with the chemotherapy drug doxorubicin for the treatment of patients with soft tissue sarcoma, an aggressive cancer in urgent need of new treatment options.
The company has a substantial arsenal of products and is channelling more funds into R&D to advance clinical trials, drug discovery and preclinical activities.
The clinical-stage drug development company is in a strong financial position following a recent R&D rebate, and is well-placed to advance a promising clinical pipeline.
The cash injection adds to Noxopharm’s robust cash position, which stood at A$23.6 million as of September 30, 2021.
“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next stages,” Dr Mautner said.
"This phase two study builds on our phase one trial, where we saw promising signals that it may be possible to achieve cancer reduction through the abscopal response,” says CMO.
RNA drugs already under development by Hudson will add to existing Pharmorage assets and help position the company at the forefront of chronic inflammatory/autoimmune diseases drug development.
“This grant not only provides substantial non-dilutive funding to Noxopharm, but it also lends external validation to our work. The MRFF awards a limited number of grants, funding only those projects that are highly rated against a series o
The company believes that DARRT-treatment has the potential to revolutionise cancer treatment by reducing cancer through the abscopal response without many of the unwanted side effects, cost limitations and logistical challenges associated
“If we can improve the performance of ICIs by the addition of Veyonda, it could make a massive impact, improving outcomes for cancer patients worldwide. It is exciting that this study is now underway in Australia, and we look forward to upd
"A high proportion of cancer patients are deprived of the benefits of chemotherapies because of toxic side-effects. Other patients either are too ill or too elderly or just unwilling to even start chemotherapy. That is the gap that we see V
The company is building a pipeline of drugs based on a unique and proprietary technology platform for large markets of unmet medical needs.
“We see the allowance of this patent application as a major win for the company in our goal of seeing DARRT therapy become a mainstream cancer treatment,” says CEO & MD.
The clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome is going into the new financial year in a strong cash position, enabling it to proceed with its exciting Four Pillars Oncology Prog
The discovery of idronoxil's anti-inflammatory mechanism adds a high-profile and potentially high-value drug target for the company’s subsidiary Pharmorage’s emerging pipeline.
Its partnership with Hudson Institute of Medical Research, NOX has also led to an important discovery about the anti-inflammatory mechanism of action of idronoxil, the active ingredient in Veyonda®.
